November 14, 2023

Risk Strategies Consulting: Q4 2023 Clinical Rx Pipeline Report

Consulting

1 min read

Stuart Piltch, President – Risk Strategies Consulting

Risk Strategies Consulting: Q4 2023 Clinical Rx Pipeline Report

Risk Strategies Consulting’s fourth-quarter Clinical Rx Pipeline Report is now available. This edition provides updates on impactful drug approvals and a forward-looking analysis of the clinical biosimilar and cell & gene therapy pipelines. In addition, the report reviews multiple topics including:

Approval of Zepbound (tirzepatide) for chronic weight management
Recent subcutaneous dosing formulation approvals that could result in a shift in spend from medical to pharmacy
A new psoriasis biologic demonstrating super efficacy to existing therapies
Approvals and upcoming launches for first-time biosimilars in 2024

As a full-service consultancy with on-staff clinicians and pharmacists for plan sponsors with mid-to-high aggregate drug spend, this knowledge is critical for managing costs and strategic planning. Our team of clinical experts is here to help.

Want to learn more?

Find Stuart Piltch on LinkedIn.

Learn more about our pharmacy consulting services, here.

The contents of this article are for general informational purposes only and Risk Strategies Company makes no representation or warranty of any kind, express or implied, regarding the accuracy or completeness of any information contained herein. Any recommendations contained herein are intended to provide insight based on currently available information for consideration and should be vetted against applicable legal and business needs before application to a specific client.

See all posts